Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 plus fulvestrant in second-line HR-positive, HER2-negative advanced breast cancer
CTR20190619Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib, fulvestrant in breast cancer, sponsored by Hengrui Therapeutics. Started Jun 2019; status: active.
02
Drugs
dalpiciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190619.